A Cost Impact Analysis of clonoSEQ(®) as a Valid and CE-Certified Minimal Residual Disease (MRD) Diagnostic Compared to No MRD Testing in Multiple Myeloma in Germany

INTRODUCTION: The measurement of minimal residual disease (MRD) with clonoSEQ(®) can be used in the assessment of B-cell lymphoid tumor burden throughout treatment with accuracy, sensitivity and standardization when compared to traditional cytomorphology. With the approval of novel treatments, stand...

Descripción completa

Detalles Bibliográficos
Autores principales: Walzer, Stefan, Krenberger, Sebastian, Vollmer, Lutz, Hewitt, Tony, Eckert, Benjamin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8593124/
https://www.ncbi.nlm.nih.gov/pubmed/34480748
http://dx.doi.org/10.1007/s40487-021-00169-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8593124/
https://www.ncbi.nlm.nih.gov/pubmed/34480748
http://dx.doi.org/10.1007/s40487-021-00169-x

Ejemplares similares